It's important to follow the treatment plan your doctor has laid out for you. You know how the joint pain and symptoms of rheumatoid arthritis (RA) can impact your daily life. Rituxan can provide up to 6 months of symptom improvement from 1 course of treatment (2 infusions given 2 weeks apart). Be sure to talk with your doctor to find out if starting and continuing treatment with Rituxan is right for you.
A study showed that at 6 months, 51% of the people taking Rituxan (plus methotrexate) experienced RA symptom improvement (called an ACR20 response), as opposed to 18% of people taking placebo + MTX.
It's important to consider how RA can affect your body in the future. Even if your symptoms are under control, RA may still be causing permanent damage to your joints. That's why it is so important to talk to your doctor about continuing with Rituxan in combination with methotrexate.
In a study, Rituxan with methotrexate was proven to slow joint damage for many patients (60%) during the first year of treatment compared to placebo + MTX (46%).
Furthermore, of the patients treated with Rituxan who had no progression in the first year, 87% also had no progression in the second year. Following 2 years of treatment with Rituxan (plus methotrexate), 57% of people did not experience further joint damage over those 2 years. Because each person is different, individual results may vary.
Rituxan can cause serious side effects, including:
Please see the Important Side Effect Information page and the Rituxan Prescribing Information and Medication Guide for additional Important Side Effect Information, including Most Serious Side Effects.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.